Drug Trial Radar · NCT06206733
ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
780
Planned (sponsor's estimate)
Start
Jan 25, 2024
Primary completion
Dec 30, 2026
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- AskGene Pharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.; Jiangsu Aosaikang Biopharmaceutical Co., Ltd
- First posted
- Jan 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, double-blind, standard-of-care controlled phase III clinical study conducted in China. The purpose of this study is to evaluate the efficacy of ASKB589 plus CAPOX and PD-1 inhibitor compared with placebo plus CAPOX and PD-1 inhibitor (as first-line treatment) as measured by Progression Free Survival (PFS).
Conditions
- Gastroesophageal Junction Adenocarcinoma
- Gastric Adenocarcinoma
Interventions
ASKB589Drug
ASKB589 will be administered as a minimum 3-hour IV infusion
OxaliplatinDrug
Oxaliplatin will be administered as a minimum 2-hour IV infusion
CapecitabineDrug
Capecitabine will be administered orally twice daily (bid).
TislelizumabDrug
Tislelizumab will be administered every 3 weeks Intravenous infusion on day 1 of each cycle.
PlaceboDrug
Placebo will be administered as a minimum 3-hour IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: Until disease progression or withdrawal from the study (generally up to 24 months)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing cancer hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.